~~<i id='80530CD7BE'><strike id='80530CD7BE'><tt id='80530CD7BE'><pre id='80530CD7BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：leisure time 2025-09-02 09:35:42 - browse：3354

Roche HQ — SEBASTIEN BOZON/AFP via Getty Images

The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： As health system earnings go up, health insurance stocks go down

explore

focus

hotspot

Wikipedia

hotspot

leisure time

AdobeThisarticleisadaptedfromSTAT’slatestreport,“2023Update:rankingbiotech’stopventurecapitalfirms.”

WSS

Wegovy cuts risk of cardiovascular events by 20%, study finds

AltruBio raises $225 million to develop ulcerative colitis drug

How a small hospital in rural Puerto Rico survived Hurricane Maria

Class action alleges UnitedHealth concealed DOJ probe

The creative science of coining drug names

Biden praises World Series champion Astros for impact off the field during White House celebration

focus

Wikipedia

explore

At least 13 dead in Texas as scorching temps continue

‘The Bear’ and hospitality in hospitals

Peter Hotez and the public health issue of online harassment

Most antidepressants don't work on kids, teens, study finds

Alkermes shareholders re

Has Bernie Sanders reached the limit of his pharma bullying effort?

Psychedelics group wrestles with new pharma identity

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Medical records are filled with copy

Empower primary care with adequate payments and technology

focus

In venture capital firm's success, lessons for turning crisis into profit

AI for drug discovery: Experts on separating hype from reality

Chemotherapy before breast cancer surgery might fuel metastasis

Sepsis can kill a child within hours. Here's how hospitals are fighting back

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

The effects of a landmark ruling on DNA ownership are becoming clearer

hotspot

Wikipedia

hotspot

leisure time